The present invention discloses an application of Antrodia cinnamomea and monomeric lanostane 32 in prevention and treatment of non-alcoholic fatty liver. The new use of Antrodia cinnamomea and monomeric lanostane 32 provided in this invention is specifically an application of an extract of Antrodia cinnamomea or the fruiting body of Antrodia cinnamomea or a monomeric compound or lanostane 32 separated from the extract of the fruiting body of Antrodia cinnamomea or a substance that contains the above substances in preparation of a product for treating and/or preventing non-alcoholic fatty liver. Experiments reveal that Antrodia cinnamomea and monomeric lanostane 32 may cause reduction of liver lipid deposition of a non-alcohol fatty liver disease organism body, reduction of total triglyceride content, and reduction of the expression level of inflammatory factors and fibrosis-related factors, and also causes reduction of the content of 4-hydroxynonenal in serum and prevents lipid deposition in the liver of the organism body caused by non-alcoholic fatty liver, and increases body weight and liver weight. It can be seen that Antrodia cinnamomea and monomeric lanostane 32 have important effects in the prevention and treatment of non-alcoholic fatty liver.本發明公開了牛樟芝及單體羊毛甾烷32在防治非酒精性脂肪肝中的應用。本發明所提供的牛樟芝及單體羊毛甾烷32的新用途具體為牛樟芝或牛樟芝的子實體提取物或從所述牛樟芝的子實體提取物中分離獲得的單體化合物或羊毛甾烷32或者含有上述各物質的物質在製備用於治療和/或預防非酒精性脂肪肝的產品中的應用。實驗證明，牛樟芝及單體羊毛甾烷32能夠使得非酒精性脂肪肝患病機體肝臟內脂質沉積量降低、總甘油三脂含量降低、炎症因子和纖維化相關因子的表達水平降低，並降低血清中4-羥基壬烯醛的含量，還能防止由於非酒精性脂肪肝引起的機體肝臟內脂質沉積，以及體重和肝臟重量增加。可見牛樟芝及單體羊毛甾烷32對於防治非酒精性脂肪肝具有重要作用。
